Human Serum Albumin as a Prodrug Carrier for Tumor Therapy: Mechanisms, Applications, and Future Perspectives
Pharmaceutics · 30.04.2026 · 18 (5) · 557
DOI: 10.3390/pharmaceutics18050557 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 30.04.2026. Verfasst von Yuhong Shang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Naval Medical University, Shanghai 200433, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human serum albumin (HSA), as a natural protein carrier, possesses excellent biocompatibility and drug binding capacity. Due to the synergistic effects of the enhanced permeability and retention (EPR) effect and Gp60/SPARC-mediated active targeting, this drug carrier demonstrates favorable tumor selectivity and can be enriched in tumor tissues to achieve long-term therapeutic effects. Particularly, HSA undergoes pH-dependent recycling through the neonatal Fc receptor (FcRn), which significantly prolongs its half-life and enhances its feasibility as a drug delivery platform. In practical clinical applications, the regulation of HSA release rates requires multiple strategies to work synergistically. Additionally, the targeting efficiency of delivery systems due to tumor heterogeneity remains a major bottleneck limiting its universality. This article systematically reviews the unique advantages, clinical applications, challenges, and future perspectives of HSA as a prodrug carrier in tumor therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- School of Nursing, Shanghai Jiguang Polytechnic College, Shanghai 201901, China.
ORCID-Profile: Lan She, Zhiqiang Ma
Zitieren
APA
Shang, Y., Wang, S., Yan, Y., Tian, E., She, L., & Ma, Z. (2026). Human Serum Albumin as a Prodrug Carrier for Tumor Therapy: Mechanisms, Applications, and Future Perspectives. Pharmaceutics, 18(5), 557. https://doi.org/10.3390/pharmaceutics18050557
Vancouver
Shang Y, Wang S, Yan Y, Tian E, She L, Ma Z. Human Serum Albumin as a Prodrug Carrier for Tumor Therapy: Mechanisms, Applications, and Future Perspectives. Pharmaceutics. 2026;18(5):557. doi:10.3390/pharmaceutics18050557
BibTeX
@article{Shang2026,
author = {Shang, Yuhong and Wang, Shuangran and Yan, Yingyi and Tian, Encheng and She, Lan and Ma, Zhiqiang},
title = {Human Serum Albumin as a Prodrug Carrier for Tumor Therapy: Mechanisms, Applications, and Future Perspectives},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {557},
doi = {10.3390/pharmaceutics18050557}
}
EUVIMED